Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Leukemia, Lymphocytic, Chronic, B-Cell 4Recurrence 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Leukemia 2Myelodysplastic Syndromes 1Mature B-Cell Malignancies 1Lymphoma, T-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1B-cell Malignancies 1

Interventions

zanubrutinib 1tirabrutinib 1obinutuzumab 1itacitinib 1idelalisib 1Voriconazole 1INCB039110 1Fluconazole 1Diltiazem 1Clarithromycin 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × B-cell Malignancies × zanubrutinib × Clear all
NCT04551963 2024-10-26

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

BeiGene

Phase 1 Completed
26 enrolled 20 charts
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡